GW Pharmaceuticals PLC- (NASDAQ:GWPH) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 12.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,014 shares of the biopharmaceutical company’s stock after selling 1,319 shares during the period. Janney Montgomery Scott LLC’s holdings in GW Pharmaceuticals PLC- were worth $1,037,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its holdings in GW Pharmaceuticals PLC- by 4.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 92 shares in the last quarter. Close Asset Management Ltd lifted its holdings in GW Pharmaceuticals PLC- by 13.5% in the 2nd quarter. Close Asset Management Ltd now owns 876 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 104 shares in the last quarter. Aperio Group LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 4.0% during the 2nd quarter. Aperio Group LLC now owns 2,763 shares of the biopharmaceutical company’s stock worth $476,000 after acquiring an additional 106 shares during the period. D.A. Davidson & CO. lifted its holdings in shares of GW Pharmaceuticals PLC- by 3.3% during the 2nd quarter. D.A. Davidson & CO. now owns 3,611 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 117 shares during the period. Finally, Rothschild Investment Corp IL lifted its holdings in shares of GW Pharmaceuticals PLC- by 0.7% during the 2nd quarter. Rothschild Investment Corp IL now owns 17,689 shares of the biopharmaceutical company’s stock worth $3,049,000 after acquiring an additional 120 shares during the period. Institutional investors own 82.89% of the company’s stock.

In related news, insider Douglas B. Snyder sold 3,756 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the transaction, the insider now directly owns 79,164 shares in the company, valued at $1,098,796.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Douglas B. Snyder sold 5,424 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $13.04, for a total value of $70,728.96. Following the transaction, the insider now owns 73,740 shares in the company, valued at $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is currently owned by company insiders.

Several brokerages have recently weighed in on GWPH. Cowen reiterated a “buy” rating and set a $200.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Friday, July 26th. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $122.00 price objective on the stock in a report on Saturday. Bank of America reiterated a “buy” rating and set a $218.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Needham & Company LLC began coverage on shares of GW Pharmaceuticals PLC- in a report on Monday, October 21st. They set a “buy” rating and a $200.00 price objective on the stock. Finally, ValuEngine upgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $198.00.

GWPH opened at $109.41 on Friday. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31. The company has a market cap of $4.16 billion, a PE ratio of -10.36 and a beta of 2.28. The firm has a 50 day moving average price of $122.70 and a 200 day moving average price of $154.23.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: What is a Candlestick Chart?

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit